Oligomeric compounds for the modulation HIF-1α expression
First Claim
1. A compound of 16 to 50 nucleotides or nucleotide analogues, wherein adjacent nucleotides or nucleotide analogues are covalently linked by an internucleotide linkage, which is capable of modulating HIF-1α
- as encoded by a nucleic acid molecule having the sequence of SEQ ID NO. 1 and wherein a region of said compound has a sequence that is identically present in SEQ ID NO;
55.
4 Assignments
0 Petitions
Accused Products
Abstract
Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
145 Citations
35 Claims
-
1. A compound of 16 to 50 nucleotides or nucleotide analogues, wherein adjacent nucleotides or nucleotide analogues are covalently linked by an internucleotide linkage, which is capable of modulating HIF-1α
- as encoded by a nucleic acid molecule having the sequence of SEQ ID NO. 1 and wherein a region of said compound has a sequence that is identically present in SEQ ID NO;
55. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 35)
- as encoded by a nucleic acid molecule having the sequence of SEQ ID NO. 1 and wherein a region of said compound has a sequence that is identically present in SEQ ID NO;
-
2. A compound of 16 to 50 nucleotides or nucleotide analogues, wherein adjacent nucleotides or nucleotide analogues are covalently linked by an internucleotide linkage, targeted to a nucleic acid molecule encoding HIF-1α
- (SEQ ID NO.
1), wherein said compound hybridizes with said nucleic acid molecule and is capable of inhibiting the expression of HIF-1α
in a cell and wherein a region of said compound has a sequence that is identically present in SEQ ID NO;
55.
- (SEQ ID NO.
-
23. A compound represented by the formula:
- TsGsGsCsasasgscsastscscsTsGsTsA (SEQ ID NO.
55) wherein uppercase letters denote oxy-LNA nucleotides, lowercase letters denote deoxynucleotides and the subscript “
s”
denotes a phosphorothioate linkage. - View Dependent Claims (25, 26, 27, 28)
- TsGsGsCsasasgscsastscscsTsGsTsA (SEQ ID NO.
-
24. A compound selected from TsGsGsCsasasgscsastscscsTsGsTsa (SEQ ID NO. 55) and tsGsGsCsasasgscsastscscsTsGsTsA (SEQ ID NO. 55) wherein uppercase letters denote oxy-LNA nucleotides, lowercase letters denote deoxynucleotides and the subscript “
- s”
denotes a phosphorothioate linkage.
- s”
-
29. A compound of 16 to 50 nucleotides or nucleotide analogues, wherein adjacent nucleotides are covalently linked by an internucleotide linkage, which is capable of modulating HIF-1α
- as encoded by the nucleic acid molecule having the sequence of SEQ ID NO. 1, wherein said compound has a sequence that is complementary to the sequence of a target site located at nucleotides 1177 to 1192 of said nucleic acid molecule, and wherein said compound comprises at least one nucleotide analogue that is an LNA unit.
- View Dependent Claims (30, 31, 32, 33, 34)
Specification